Analyst Sentiment Improves on Arcus Biosciences as Price Targets Rise with Strong Trial Data

Arcus Biosciences' updated analyst price target has been trimmed slightly to around $34.00, as analysts factor in mixed readthroughs from recent Merck-related trial updates, a modest adjustment in long term revenue and margin assumptions, and a higher projected future P/E multiple.

Analyst Commentary

Recent Street research around Arcus Biosciences reflects a mix of optimism and caution, with analysts reassessing price targets and ratings in light of recent clinical updates tied to Merck trials and Arcus specific developments.

Bullish Takeaways

• Some bullish analysts view the recent Merck study miss as having limited direct readthrough for Arcus, which supports the case that Arcus trial outcomes and revenue potential should be assessed on their own fundamentals rather than external partnerships alone.
• Positive commentary highlights that recent Merck related setbacks may still carry some upside angles for Arcus, for example by clarifying competitive positioning or patient populations. These analysts see that as supportive of the longer term growth story being reflected in their targets.
• Certain bullish analysts have raised price targets into the low to mid US$40s and placed the stock on preferred idea lists. This signals confidence that Arcus can execute on its pipeline plans and potentially justify higher P/E assumptions over time.
• Supportive views generally tie higher targets to an expectation that Arcus can convert its pipeline into future revenue streams, with current valuation seen by these analysts as leaving room for upside if key trials deliver as planned.

Bearish Takeaways

• Bearish analysts have taken a more conservative stance following recent updates, trimming price targets by a few dollars and signaling that prior expectations around revenue and margins may have been too optimistic.
• Some have moved to more cautious ratings, emphasizing execution risk around the pipeline and uncertainty on how much Merck related trial outcomes might ultimately influence Arcus partner economics and long term cash flows.
• Where targets have been lowered, analysts are effectively signaling that at prior valuation levels the risk reward looked less attractive and that investors should factor in a wider range of potential clinical and commercial outcomes.
• Cautious commentary also points to the possibility that, if trial timelines slip or results do not meet prior assumptions, the current valuation could prove demanding relative to future earnings, even with a higher projected P/E multiple built into some models.

What’s in the News

• Gilead chose not to make an option continuation payment under the 2020 Option, License and Collaboration Agreement. As a result, its option rights to Arcus’s early stage CCR6, CD89 and CD40L programs will end on July 14, 2026, while time-limited options to AB801, AB598, AB102 and a TNF inhibitor remain in place. Arcus retains full rights to casdatifan outside territories licensed to Taiho. (Key Developments)
• A Phase 3 STAR-121 study of domvanalimab plus zimberelimab and chemotherapy in first-line metastatic non-small cell lung cancer is being discontinued for futility, along with the Phase 2 EDGE Lung study, following an Independent Data Monitoring Committee review. Zimberelimab plus chemotherapy performed consistently on overall survival compared with pembrolizumab plus chemotherapy, and no new safety issues were identified in regular safety reviews. (Key Developments)
• Arcus filed a US$200 million at-the-market follow-on equity offering of common stock. (Key Developments)
• Arcus issued a broad pipeline update, including Phase 1/1b ARC-20 data for casdatifan in late-line kidney cancer. The 100 mg once-daily cohort reported a median progression-free survival of 15.1 months and a confirmed overall response rate of 45%. Arcus also reported ongoing global enrollment in the Phase 3 PEAK-1 study, plans for an additional Phase 3 trial in first-line metastatic kidney cancer by the end of 2026, and multiple planned data readouts for casdatifan in 2026. (Key Developments)
• A new analysis from the ARC-20 study linked the magnitude and durability of erythropoietin suppression by casdatifan with clinical benefit in metastatic clear cell renal cell carcinoma. Updated data as of January 30, 2026 showed a confirmed overall response rate of 45% and median progression-free survival of 15.1 months in the 100 mg once-daily cohort, and a pooled confirmed overall response rate of 35% and median progression-free survival of 12.2 months across four cohorts. An acceptable and manageable safety profile was reported across doses. (Key Developments)

Valuation Changes

• Fair Value: Trimmed slightly from $34.20 to $34.00 per share, reflecting modest model adjustments.
• Discount Rate: Adjusted marginally from 7.27% to 7.26%, indicating a very small change in the risk assumption used.
• Revenue Growth: Long term revenue growth assumption now reflects a slightly larger decline, shifting from a 10.25% decline to a 10.79% decline.
• Net Profit Margin: Target net profit margin has been reduced from 14.82% to 12.92%, implying a more cautious view on long term profitability.
• Future P/E: Assumed future P/E multiple has moved higher from 244.0x to 283.4x, resulting in a higher valuation multiple despite the more conservative growth and margin assumptions.